Cormac S Long

US Patent:

20180110724, Apr 26, 2018

Filed:

Dec 20, 2017

Appl. No.:

15/848819

Inventors:

- St-Laurent, CA
Nadine Paiement - St-Laurent, CA
Cormac Long - Parsippany NJ, US
Rodolphe Obeid - Pierrefonds, CA

Assignee:

Intelgenx Corp. - St-Laurent

International Classification:

A61K 9/00
A61K 9/14
A61K 9/70
A61K 31/4985
A61K 31/4709
A61K 31/58
A61K 31/19
A61K 31/40
A61K 31/34
A61K 31/496
A61K 31/439
A61K 31/553
A61K 31/353
A61K 47/14

Abstract:

Oral film dosage forms that provide improved solubilization and stabilization of an active ingredient in particle form include at least one primary crystallization inhibitor in an amount that inhibits growth and/or agglomeration of the active ingredient, a polyoxyethylated fatty acid glycerides in an amount that further enhances inhibition of crystallization, growth and agglomeration of the particles of the pharmaceutically active ingredient; and at least one plasticizer present in an amount that is effective to increase flexibility and elasticity of the film dosage form.

US Patent:

20180078549, Mar 22, 2018

Filed:

Nov 27, 2017

Appl. No.:

15/822734

Inventors:

- St-Laurent, CA
Nadine Paiement - St-Laurent, CA
Angela Angusti - Montreal, CA
Cormac Long - Parsippany NJ, US

Assignee:

Intelgenx Corp. - St-Laurent

International Classification:

A61K 31/4985
A61K 9/00

Abstract:

Improved pharmaceutical solid oral dosage forms for the buccal and/or sublingual delivery of Tadalafil. The improved delivery systems for solubilizing and stabilizing pharmaceutically active ingredients exhibit enhanced methods of preparation by the use improved solubilization systems which can maintain the Tadalafil in a buccal and/or sublingual oral dosage form or a polymeric film matrix that provides improved bioavailability and/or absorption of Tadalafil.

US Patent:

20170157119, Jun 8, 2017

Filed:

Feb 7, 2017

Appl. No.:

15/426149

Inventors:

- Saint-Laurent, CA
Nadine Paiement - St-Laurent, CA
Angela Angusti - Montreal, CA
Cormac Long - Parsippany NJ, US
Rodolphe Obeid - St-Laurent, CA

Assignee:

Intelgenx Corp. - Saint-Laurent

International Classification:

A61K 31/4985
A61K 47/14
A61K 47/44
A61K 47/12
A61K 47/10
A61K 9/00
A61K 47/26

Abstract:

Oral film dosage forms that provide improved solubilization and stabilization of an active ingredient in particle form include at least one primary crystallization inhibitor in an amount that inhibits growth and/or agglomeration of the active ingredient, a polyoxyethylated fatty acid glycerides in an amount that further enhances inhibition of crystallization, growth and agglomeration of the particles of the pharmaceutically active ingredient; and at least one plasticizer present in an amount that is effective to increase flexibility and elasticity of the film dosage form.